Oscar Health Inc. reported fourth‑quarter and full‑year 2025 results that fell short of analyst expectations. Q4 revenue was $2.81 billion, down from the consensus estimate of $3.21 billion, while the company posted a GAAP earnings‑per‑share loss of $1.24 versus the $-0.84 estimate. The full‑year 2025 net loss widened to $443.2 million, a sharp reversal from the $25.4 million profit reported in 2024. Medical‑loss ratio climbed to 95.4% in Q4 and 87.4% for the year, and the SG&A expense ratio improved to 18.2% in Q4 and 17.5% for the year.
The revenue miss was driven by higher-than‑expected medical costs and a shift in the mix of premium‑based products. The individual‑market segment, which accounts for the majority of revenue, experienced a 17.4% year‑over‑year increase to $2.81 billion, but the growth was offset by a 3.2% decline in the small‑group business after the termination of the Cigna+Oscar partnership. Pricing pressure in the individual market, coupled with a higher utilization rate, pushed the medical‑loss ratio up, eroding the margin that had been improving in prior quarters.
The widening net loss reflects a combination of elevated medical costs, higher risk‑adjustment payouts, and a one‑time charge for restructuring of the small‑group portfolio. The 95.4% MLR in Q4 indicates that medical expenses consumed almost all premium income, leaving little room for operating profit. The company’s SG&A ratio improvement shows disciplined cost management, but the gains were insufficient to offset the steep rise in medical spending, which was driven by increased market morbidity and higher utilization of high‑cost services.
On February 6, 2026, Oscar Health secured a $475 million three‑year revolving credit facility, expandable by $100 million, to strengthen its balance sheet and support long‑term growth initiatives. The facility provides liquidity for general corporate purposes and signals management’s confidence in the company’s ability to navigate short‑term cash‑flow pressures while investing in technology and member experience enhancements.
The company’s 2026 outlook is markedly optimistic. Management projects full‑year revenue of $18.7 billion to $19.0 billion, a 61% year‑over‑year increase at the midpoint, and operating earnings of $250 million to $450 million. The guidance reflects confidence that the 2025 “reset” year will translate into a return to profitability, driven by record membership growth, AI‑enabled cost controls, and a more favorable risk‑adjustment environment. CEO Mark Bertolini emphasized that the new product suite and AI features are key to sustaining the membership momentum and improving margins.
Investor sentiment was mixed. The earnings miss and high medical‑loss ratio raised concerns about short‑term profitability, while the strong 2026 guidance and liquidity boost tempered the reaction. Analysts noted that the company’s ability to convert membership growth into profitability will be closely watched in the coming quarters.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.